Monthly Archives: November 2021

Molnupiravir efficacy: an update

Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com    SPECIAL REPORT #21.25     Molnupiravir efficacy: an update     On November 9, we wrote that the United Kingdom was the first country in the world to approve molnupiravir for the treatment of mild COVID-19, based on an interim analysis which showed that the antiviral […]

read more

The U.K. approves Molnupiravir for the treatment of COVID-19

  Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com      SPECIAL REPORT #21.24     The United Kingdom approves Molnupiravir for the treatment of COVID-19       The United Kingdom is the first country in the world to approve molnupiravir for the treatment of mild COVID-19. The drug, which has been known for […]

read more

MEETING US AT BIOTECHGATE DIGITAL PARTNERING NOV29-DEC3, 2021

You plan to increase your footpring on new territories in EU or US market ? to launch a new technology, a service or product on the market ? Let's meet at BIOTECHGATE DIGITAL PARTNERING NOV29-DEC3, 2021 ! Please send me an email: na [ att] btobioinnovation.com or through the business partnering tool( https://partnering.biotechgate.com/). Best regards, […]

read more

Alzheimer’s disease treatments (Part 3)

, Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com        SPECIAL REPORT #21.23     Alzheimer’s disease treatments (Part 3)     In our report #21.18, we had indicated that: “It is possible to identify other trends flowing from the decision of the FDA to approve Aduhelm that may have lasting impact. Firstly, […]

read more